Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1997 1
1998 1
1999 1
2000 1
2001 1
2002 1
2003 4
2004 2
2005 6
2006 5
2007 7
2008 5
2009 7
2010 10
2011 10
2012 7
2013 10
2014 8
2015 16
2016 16
2017 17
2018 17
2019 29
2020 35
2021 32
2022 36
2023 47
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

286 results

Results by year

Filters applied: . Clear all
Page 1
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaçi D, Morita A, Szepietowski JC, Imafuku S, Colston E, Throup J, Kundu S, Schoenfeld S, Linaberry M, Banerjee S, Blauvelt A. Armstrong AW, et al. Among authors: thaci d. J Am Acad Dermatol. 2023 Jan;88(1):29-39. doi: 10.1016/j.jaad.2022.07.002. Epub 2022 Jul 9. J Am Acad Dermatol. 2023. PMID: 35820547 Free article. Clinical Trial.
Lichen sclerosus: The 2023 update.
De Luca DA, Papara C, Vorobyev A, Staiger H, Bieber K, Thaçi D, Ludwig RJ. De Luca DA, et al. Among authors: thaci d. Front Med (Lausanne). 2023 Feb 16;10:1106318. doi: 10.3389/fmed.2023.1106318. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36873861 Free PMC article. Review.
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE, Kataoka Y, Chu CY, DiBonaventura M, Rojo R, Antinew J, Ionita I, Sinclair R, Forman S, Zdybski J, Biswas P, Malhotra B, Zhang F, Valdez H; JADE COMPARE Investigators. Bieber T, et al. Among authors: thaci d. N Engl J Med. 2021 Mar 25;384(12):1101-1112. doi: 10.1056/NEJMoa2019380. N Engl J Med. 2021. PMID: 33761207 Clinical Trial.
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Silverberg JI, et al. Among authors: thaci d. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, Ardeleanu M, Weinstein SP, Pirozzi G, Guttman-Yassky E, Suárez-Fariñas M, Hager MD, Stahl N, Yancopoulos GD, Radin AR. Beck LA, et al. Among authors: thaci d. N Engl J Med. 2014 Jul 10;371(2):130-9. doi: 10.1056/NEJMoa1314768. N Engl J Med. 2014. PMID: 25006719 Free article. Clinical Trial.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA. Strober B, et al. Among authors: thaci d. J Am Acad Dermatol. 2023 Jan;88(1):40-51. doi: 10.1016/j.jaad.2022.08.061. Epub 2022 Sep 14. J Am Acad Dermatol. 2023. PMID: 36115523 Free article. Clinical Trial.
The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease.
Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, Burisch J, De Vos M, De Vries AM, Dick AD, Juillerat P, Karlsen TH, Koutroubakis I, Lakatos PL, Orchard T, Papay P, Raine T, Reinshagen M, Thaci D, Tilg H, Carbonnel F; European Crohn’s and Colitis Organisation. Harbord M, et al. Among authors: thaci d. J Crohns Colitis. 2016 Mar;10(3):239-54. doi: 10.1093/ecco-jcc/jjv213. Epub 2015 Nov 27. J Crohns Colitis. 2016. PMID: 26614685 Free PMC article. No abstract available.
Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial.
Ezzedine K, Peeva E, Yamaguchi Y, Cox LA, Banerjee A, Han G, Hamzavi I, Ganesan AK, Picardo M, Thaçi D, Harris JE, Bae JM, Tsukamoto K, Sinclair R, Pandya AG, Sloan A, Yu D, Gandhi K, Vincent MS, King B. Ezzedine K, et al. Among authors: thaci d. J Am Acad Dermatol. 2023 Feb;88(2):395-403. doi: 10.1016/j.jaad.2022.11.005. Epub 2022 Nov 9. J Am Acad Dermatol. 2023. PMID: 36370907 Free article. Clinical Trial.
Dupilumab in Inflammatory Skin Diseases: A Systematic Review.
Olbrich H, Sadik CD, Ludwig RJ, Thaçi D, Boch K. Olbrich H, et al. Among authors: thaci d. Biomolecules. 2023 Mar 31;13(4):634. doi: 10.3390/biom13040634. Biomolecules. 2023. PMID: 37189381 Free PMC article. Review.
Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases.
Ujiie H, Rosmarin D, Schön MP, Ständer S, Boch K, Metz M, Maurer M, Thaci D, Schmidt E, Cole C, Amber KT, Didona D, Hertl M, Recke A, Graßhoff H, Hackel A, Schumann A, Riemekasten G, Bieber K, Sprow G, Dan J, Zillikens D, Sezin T, Christiano AM, Wolk K, Sabat R, Kridin K, Werth VP, Ludwig RJ. Ujiie H, et al. Among authors: thaci d. Front Med (Lausanne). 2022 Jun 9;9:875492. doi: 10.3389/fmed.2022.875492. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35755063 Free PMC article. Review.
286 results